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Abstract  
 
 Hepatocyte growth factor (HGF) and its receptor, Met, are key determinants of distinct 
developmental processes. Although HGF is cardio-protective in a number of cardiac pathologies, it 
remains unknown whether HGF/Met signaling is essential for myocardial development or normal 
physiological function in adults. We investigated the requirement of HGF/Met signaling in 
cardiomyocyte for heart development and heart function in adult mice. We inactivated Met receptor in 
cardiomyocytes by conditional deletion of the floxed c-met exon 16 using the Cre-α−MHC mouse line 
(termed α−MHCMet). Although α−MHCMet mice showed normal heart development and were viable 
and fertile, by 6 months of age males developed cardiomyocyte hypertrophy, associated with 
interstitial fibrosis. A significant upregulation in the markers of myocardial damage β-MHC, ANF, 
and connexin-43 was also observed. By the age of 9 months, α−MHCMet mutant males displayed  
systolic cardiac dysfunction. Mechanistically, we provide evidence of a severe imbalance in the 
antioxidant defenses in α−MHCMet hearts involving a reduced expression and activity of catalase and 
superoxide dismutase, with consequent reactive oxygen species accumulation. Similar anomalies were 
observed in females, although with a slower kinetics.  We also show that Met signaling down-
regulation leads to an increase in TGF-β production and a decrease in p38MAPK activation, which 
may contribute to phenotypic alterations displayed in α−MHCMet mice. In fact, HGF acting through 
p38α upregulated antioxidant enzymes in cardiomyocytes. Our results highlight that HGF/Met 
signaling in cardiomyocytes plays a physiological cardio-protective role in adult mice by acting as an 
endogenous regulator of heart function through the control of oxidative stress.  
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Introduction  
 The hepatocyte growth factor (HGF) receptor, Met, is a tyrosine kinase receptor expressed in a 
wide variety of cell types. It regulates several cellular functions, including proliferation, scattering, 
differentiation and “invasive growth”, either during development or under some pathological 
conditions [1-4]. Upon HGF binding, Met is autophosphorylated in different tyrosine residues, leading 
to the recruitment of several SH2-domain containing proteins through the multifunctional docking site 
located in its carboxy-terminal tail [5]. Both HGF and Met are essential during development as shown 
by the embryonic lethality of met or hgf mutant mice that display defects in placenta, liver, and muscle 
[6-11]. This embryonic lethality imposes the use of conditional inactivation strategies to explore its 
functional requirement during embryogenesis or after birth. 
 HGF protects rats from myocardial infarction [12] and/or ischemia/reperfusion injury [13]. 
Post-infarction treatment with HGF improves left ventricular remodeling and heart function in mice 
[14]. In addition, HGF also improved heart functionality and promoted proliferation of myocardial 
progenitor cells in doxorubicin-induced cardiomyopathy [15]. Moreover, in a hamster model of 
cardiomyopathy, treatment with HGF prevented heart fibrosis, remodeling, and dysfunction [16]. 
Together, these findings indicate that HGF/Met axis exerts a cardio-protective role under pathological 
conditions. On the other side, some in vitro data showed that HGF induced the expression of cardiac 
markers in mesenchymal stem cells [17] and increased cardiac differentiation of embryonic stem cells 
[18]. Both HGF and Met are expressed in cardiac myocytes during early cardiogenesis [19,20]. Recent 
data indicated that neonatal cardiomyocytes express Met and respond to HGF by increasing 
proliferation in a mouse model of HGF supra-physiological overexpression [21]. Although these 
results suggest that enhanced HGF/Met signaling impacts heart development, it remains unknown 
whether endogenous activity levels of HGF/Met is required for heart development and/or physiology 
after birth.  
 In this study, we evaluated genetically the role played by the HGF/Met axis in the developing 
and adult heart using a conditional knock-out mouse model lacking Met signaling in cardiomyocytes. 
This was accomplished by the conditional deletion of c-met exon 16 from c-met flox/flox mice [22] by 
employing a transgenic line expressing the Cre recombinase under the control of the α-myosin heavy 
chain (α-MHC) promoter [23]. Exon 16 encodes a residue in the Met kinase domain that is critical for 
the binding of ATP and therefore for the tyrosine kinase activity of the receptor. On the other hand, the 
α-MHC promoter is active in mouse embryos throughout the myocardium starting from E8 [24]. 
Previous reports have shown that by E12.5, α-MHC is highly expressed in atria and to a lesser extent 
in the ventricles, whereas its expression increases in the ventricles after birth [25]. Therefore, the α-
MHC-Cre line allows c-met inactivation in cardiomyocytes at early heart developmental stages.  
 Using the conditional α−MHCMet mouse model, we found that while Met signaling in 
cardiomyocytes appears to be dispensable for heart development, it is required to protect 
cardiomyocytes from oxidative stress, thus preventing cardiomyocyte hypertrophy, heart fibrosis, and 
heart dysfunction in adult mice. Together, these studies unveil that HGF/Met signaling in 
cardiomyocytes is a key regulator for proper heart function.     
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Materials and methods  
Generation of cardiomyocyte c-met knock-out mice and genotyping 
 The animals used in our research program were handled in compliance with the institutional 
and European Union guidelines for animal care and welfare. All mouse lines were maintained and 
bred at the UCM facility, allowed food and water ad libitum and routinely screened for pathogens in 
accordance with FELASA (Federation of European Laboratory Animal Science Associations) 
procedures.  
 c-met flox/flox (wt) mouse line (in a CD1 genetic background), which carries c-met alleles with 
exon 16 flanked by loxP sites was obtained from Dr. S. Thorgeirsson [22]. This mouse was crossed 
with α-MHC-Cre transgenic mouse in CD1 background (obtained from Dr. M. D. Schneider [23]) to 
generate α-MHC-Cre/+: c-met flox/+ mice, which were then crossed with c-met flox/flox mice. Cre-
mediated excision led to a null allele for c-met, which encodes an inactive Met receptor only in 
cardiomyocytes. Mice genotyping was performed by PCR analysis (supplemental detailed methods).  
RT-qPCR analysis  
 After the isolation of total RNA, DNA and proteins using AllPrep DNA/RNA/Protein Mini Kit, 
RNA was reverse transcribed using SuperScript III RT kit (Quiagen, 18080) to generate cDNA. Then, 
Real Time PCR was performed using specific primers (see supplemental methods). Quantification was 
performed calculating RQ (2-ΔΔCt), so referring the values to control mice (supplemental methods). An 
Invitrogen custom RNA profiling by RT-qPCR was performed for the analysis of anti- and pro-fibrotic 
genes and those involved in reactive oxygen species (ROS) metabolism (supplemental methods).    
Western-blot analysis 
 Western-blot analysis was carried out as previously described [26]. Proteins were separated by 
electrophoresis using Anderson or SDS-page gels, and transferred to nitrocellulose membranes that 
were probed with the following antibodies: catalase (Sigma, C0979), superoxide dismutase-2 (SOD-2) 
(Upstate Biotech, 06-984), β-actin (Sigma A5441), c-Met (Santa Cruz Biotechnology sc-260), 
cytochrome c (BD 556433), porin (Sigma V2139), phospho-p38MAPK (Cell Signaling, 9211), p38α 
(Santa Cruz Biotechnology sc-535).  
Histology 
 Hearts were processed for histology using conventional techniques involving paraformaldehyde 
fixation and paraffin embedding. The degree of interstitial fibrosis was assessed by image analysis on 
Mallory's trichrome stained tissue sections (see supplemental methods). Laminin immunostaining of 
heart sections was done to delineate the cardiomyocyte profiles, measuring their areas with the ImageJ 
analysis package. Apoptotic cardiomyocytes were detected by using anti-desmin (Sigma, D1033) and 
anti-active caspase-3 antibodies (Promega, G74819).  
ROS detection and quantification  
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 Reactive oxygen species (ROS) accumulation in hearts was detected by staining of frozen 
sections with hydroxyethidine or by immunolocalization of 4-OH-Nonenal (Alpha Diagnostics, 
HNE11-S) in paraffin sections. Stained areas were assessed on digitalized images using ImageJ 
software.  
  Carbonylated proteins were quantified as an indirect measurement of ROS [27]. Heart extracts 
were treated with 2,4-Dinitrophenylhydrazine or maintained untreated (blank). Then, proteins were 
precipitated with TCA and absorbance at 360 nm was determined. The concentration of carbonylated 
proteins was calculated upon correction with the blanks and referred to protein content (supplemental 
methods).  
Measurement of catalase, SOD, and cytochrome c oxidase activities  
 Catalase activity was measured by quantification of peroxide decomposition 
spectrophotometrically at 240 nm. Superoxide dismutase (SOD) activity was quantified using a Kit 
(BioVision) (supplemental methods). Cytochrome c oxidase activity was determined by quantification 
of cytochrome c oxidation spectrophotometrically at 550nm. 
Electrocardiographic measurements in conscious mice using radiotelemetry 
  Telemetric electrocardiogram (ECG) recordings in conscious mice were carried out using an 
implantable telemetry system with ECG transmitters (ETA-F10) (Data Sciences International, St Paul, 
MN, USA). Recordings were taken every 3 h, 5 min/each, over a 24 h period and analyzed using 
ECG-auto software supplied by Data Systems (supplemental methods).  
Echocardiographic assessment of cardiac function and structure 
 Transthoracic echocardiography was performed on lightly anesthetized mice using a Vivid 7 
(GE Medical Systems) cardiac ultrasound machine equipped with a 10-14-MHz transducer il3L (GE 
Medical Systems), as previously described [28]. Measurements of chamber dimensions and cardiac 
function were made offline (EchoPac Software, GE Medical Systems). Structural and functional heart 
parameters were calculated as previously described [28] (supplemental methods). 
Assays in cardiomyocytes derived cell lines 
 Cardiomyocyte cell lines (wt and p38α-/-) were generated from E9.5 immortomouse embryos 
expressing a temperature-sensitive large T antigen (LTAg) [29]. Before the experiments, cells were 
transferred to 37°C in the absence of IFN-γ to abolish LTAg expression. Neonatal cardiomyocyte cell 
lines were obtained by immortalization of neonatal mice (P4) cardiomyocytes by transfection with 
LTAg. For the experiments, all the cell lines were maintained in a low serum medium (2%) and 
treated with the Met inhibitor SU11274 (5µM) or TGF-β (1ng/mL) in the presence or absence of HGF 
(30ng/mL, 16h pretreatment) or N-acetyl cysteine (2.5mM) for 1-4 days as indicated.  
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Results  
Conditional inactivation of Met in cardiomyocytes does not overtly affect embryonic and 
postnatal heart development, but leads to cardiac anomalies in adult mice 
 To selectively inactivate Met signaling in cardiomyocytes and bypass embryonic lethality due to 
other organs defects, we used the combination of a conditional c-met allele (c-metfl) [22] and a Cre 
recombinase under the α-MHC promoter [23] mice. The resulting α−MHCcre:metfl/fl conditional 
knockout will be herein referred as α−MHCMet. Because some strains of  transgenic α−MHCcre mice 
expressing very high levels of Cre-recombinase in cardiomyocytes have been described to present 
heart anomalies [30], we checked the hearts from our  α−MHCcre mice. They were similar to metfl/fl 
(considered as wt controls) in all experiments performed (supplemental fig. 1). So, both were 
indistinctly used as controls.    
 Efficiency of the c-met deletion was determined by PCR and Western-blot analysis. Exon 16 
was deleted at E15.5 as detected by the presence of the deletion-specific band. Consistently, western-
blot analysis showed a sharp decrease in c-Met protein levels in E15.5 α−MHCMet mutant embryos 
(Fig. 1a), confirming the efficient deletion of Met, as shown in other Cre lines [22,31]. Quantification 
revealed a c-Met deletion of 60%-80% and 80-95% in embryonic (E15.5) and adult 
α−MHCMet hearts, respectively (data not shown). Probably, most of this remaining c-Met expression 
occurs in non-cardiomyocyte cells. No significant differences were found between controls and 
α−MHC-Met mutants either during development or after birth (Fig. 1b and c). These data indicate that 
c-Met signaling in cardiomyocytes is dispensable for heart development. 
 Conditional α−MHCMet mutants were born following a mendelian ratio, have a normal lifespan 
and weight curve (not shown), thus indicating that other tissues has been preserved from Met 
inactivation. Therefore, the α−MHCMet mutant mice represent a unique genetic setting to investigate 
Met signaling requirement for heart function. This issue was assessed by performing a series of 
morphological, molecular, and functional studies on 3, 6, and 9 months old α−MHCMet mice. It is 
well know that the gender may influence the molecular process underlying heart function, as shown by 
a number of studies in mice [32-34]. We therefore first focused our analysis on α−MHCMet males. 
Whereas morphological analysis of the heart did not reveal significant abnormalities in 3 months old 
α−MHCMet males, we observed structural abnormalities in 6 months old α−MHCMet mutant hearts 
(Fig. 2a, b, d). In particular, a significant increase in the cross-sectional area of cardiomyocytes was 
observed in α−MHCMet mutant hearts from 6 and 9 months old males compared to controls (Fig. 2b, 
c and supplementary fig. 2a). In addition, myocardial fibrosis, extensive areas with cardiomyocyte 
disorganization and strong collagen deposition were also found in the heart of 6 and 9 months old 
α−MHCMet males compared to controls (Fig. 2d, e and supplementary fig. 2b). As fibrosis can be a 
physiological response to cardiomyocyte death, we analyzed the presence of active caspase-3 in cells 
and found increased levels in the fibrotic areas of hearts from α−MHCMet mutant males compared to 
controls (Fig. 2f).  
 We next asked whether morphological defects observed in α−MHCMet males were parallel to 
heart dysfunction markers. In particular, we performed RT-qPCR studies to assess the levels of β-
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MHC and atrial natriuretic factor (ANF), known to be induced during hypertrophy, and of connexin 43 
(Cx43), which becomes up-regulated in compensated hypertrophy [35,36]. No differences were 
observed in 3 months old mutants (Fig. 2g). In contrast, we found increased mRNAs expression levels 
of Cx43, ANF, and β-MHC in the heart of 6 months old α−MHCMet males compared to controls (Fig. 
2g). Moreover, RT-qPCR analysis of the expression of pro-fibrotic genes such as TGF-β2 and TGF-
β3, or fibrotic markers such as α-smooth muscle actin (Acta-2) revealed significantly increased levels 
in α−MHCMet males compared to controls (Fig. 2h).  
 We next assessed whether these morphological and molecular alterations impacted the heart 
electrical function by performing electrocardiography (ECG) analyses. Whereas ECG was normal in 3 
months old α−MHCMet mice (data not shown), we found specific alterations in 6 months old 
α−MHCMet males. Anomalies consisted in the reduction or disappearance of the J wave [37] and a 
deepening of the S-P interval, usually reaching -0.2 mV (Fig. 3a). However, data from 
echocardiographic analysis demonstrated no significant differences in cardiac output or left ventricular 
mass in α−MHCMet males (not shown). In contrast, echocardiographic analyses of 9 months old 
α−MHCMet males revealed signs of systolic dysfunction characterized by a significantly higher left 
ventricular systolic diameter and volume compared to controls. Shortening fraction and ejection 
fraction were also significantly decreased (Fig. 3b and c).  
 Morphological, molecular, and functional studies were also performed in females. Increased 
cardiomyocyte size and extensive areas of fibrosis were detected in 9 months old females 
(Supplementary fig. 3a-c). Echocardiographic analysis revealed no significant differences between 
α−MHCMet and controls, although a similar tendency as that found in mutant males was observed 
(data not shown). Together, these studies showed that HGF/Met signaling in cardiomyocytes is 
dispensable during development and in young mice, whereas it is required for proper heart function in 
adult mice. Moreover, they indicate that males are more susceptible to altered HGF/Met signaling than 
females.      
 
Loss-of-function of Met signaling disrupts the antioxidant defenses in cardiomyocytes, leading to 
an increase in ROS accumulation and altered mitochondria in adult mice heart 
 The oxidative stress increases during aging, leading to cardiac alterations, including 
hypertrophy and heart dysfunction [38]. As HGF/Met signaling regulates the antioxidant defenses in 
different cells types by preventing ROS accumulation [39-41], we investigated whether heart defects 
observed in adult α−MHCMet males were linked to an imbalance in pro- and anti-oxidant 
mechanisms. We found that expression levels of antioxidant enzymes such as catalase and SOD-2 
were decreased in the heart of 6 months old α−MHCMet males compared to controls (Fig. 4a). 
Consistently, catalase and SOD-2 activities were also decreased in α−MHCMet males (Fig. 4b). We 
also found that reactive oxygen species were accumulated in cardiomyocytes of α−MHCMet males as 
shown by 2-hydroethidine staining and 4-OH-nonenal immunolocalization in tissue sections from 6 
and 9 months old mice, respectively  (Fig. 4c and d). In addition, carbonylated protein levels increased 
in 6 months old mutant males (Fig.4e), as a readout of proteins oxidation by ROS. 
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 Because ROS accumulation can be either a consequence of an altered mitochondrial function 
and/or can lead to mitochondrial damage, we next investigated whether α−MHCMet 6 months old 
male hearts presented alterations in mitochondria. We found that the mitochondrial proteins porin and 
cytochrome c were significantly decreased in mutants as compared to controls (Fig. 4f). Consistently, 
cytochrome c oxidase activity was significantly reduced in α−MHCMet mutant hearts (Fig. 4g). In 
contrast, we did not observe any alteration in anti-oxidant enzymes, ROS accumulation, carbonylated 
proteins or mitochondrial proteins in 6 months old α−MHCMet females, consistent with normal 
morphology and function, as previously assessed (Supplementary fig.3). However, in 9 months old 
mutant female hearts antioxidant enzymes levels significantly decreased and ROS accumulation was 
detected (Supplementary fig. 4c), accordingly with the detection of fibrosis and the increased 
cardiomyocytes size (Supplementary fig. 3) Altogether, these findings strongly indicate that HGF/Met 
signalling is required for normal mitochondrial function and redox homeostasis in adult 
cardiomyocytes. 
 
Met acts on p38 MAPK to increase antioxidant enzymes levels and counteracts TGF-β  effect in 
cardiomyocytes 
 We next aimed at uncovering the molecular mechanism by which HGF/Met signaling in 
cardiomyocytes ensures proper levels of antioxidant enzymes. As it has been shown that p38α MAPK 
regulates the expression of SOD-2 and catalase in mouse embryonic fibroblast (MEFs) [42], we 
assessed p38α MAPK signaling in control and α−MHCMet mutant hearts. Notably, we found that 
p38α MAPK phosphorylation levels were significantly decreased in α−MHCMet hearts from 6 and 9 
months old mice (Fig. 5a and Supplementary fig. 4g). We therefore studied whether p38α was 
required for HGF/Met-mediated regulation of antioxidant enzymes in cardiomyocytes through 
applying pharmacological approaches on embryonic cardiomyocyte cell lines generated from wild-
type or p38α deficient mice (p38α-/-). We found decreased levels of catalase and SOD-2 proteins in 
p38α-/- cardiomyocytes compared to controls (Fig. 5b and c). Met inhibition with SU11274 treatment 
reduced the levels of catalase, SOD-2, and phospho-p38α MAPK in wild-type cells, but not in p38α-/- 
mutant cells (Fig. 5b and c). These findings were further confirmed using neonatal cardiomyocytes 
(data not shown). HGF stimulation increased the levels of catalase and SOD-2 proteins in wt, but not 
in p38α-/- cardiomyocytes (Fig. 5c). Thus, HGF/Met acts through p38 MAPK to increase catalase and 
SOD-2 levels. 
 The increased levels of TGF-β isoforms observed in α−MHCMet mutant hearts (Fig. 2h) 
prompted us to investigate whether the levels of antioxidant enzymes were influenced by TGF-β. 
Notably, we found that TGF-β led to a decrease in catalase and SOD-2 protein levels in both wild-type 
and p38α-/- cardiomyocytes (Fig. 5d). In contrast, TGF-β treatment did not modify phospho-p38α 
levels significantly (Fig. 5d). Moreover, HGF prevented the decrease in catalase and SOD-2 protein 
levels mediated by TGF-β, only in wt cardiomyocytes (Fig. 5e).  
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 Taken together, these findings indicate that HGF/Met acts through p38 MAPK to increase the 
levels of antioxidant enzymes in cardiomyocytes, possibly by counteracting the effects elicited by 
TGF-β. 
 
Increased cardiomyocyte size occurring in the absence of Met signaling is prevented by 
antioxidant treatment 
 As alteration of Met signaling in cardiomyocytes leads to decreased antioxidant enzymes 
levels, it is tempting to speculate that accumulation of ROS in α−MHCMet mutant hearts could be 
responsible for the increased size of cardiomyocytes. This would be coherent with previous studies 
showing that ROS accumulation is responsible for cardiomyocyte hypertrophy as happens in Sirt3-
deficient mice [43]. We therefore tested this hypothesis using wild-type neonatal cardiomyocyte cell 
lines. We found that Met inhibition led to increased cell size in a time-dependent manner (Fig. 6a). 
Treatment of cardiomyocytes with the antioxidant N-acetyl-cysteine prevented the increased size of 
cells exposed to Met inhibitors (Fig. 6b). These findings support that ROS accumulation might 
account for the cardiomyocyte hypertrophy occurring in the absence of HGF/Met signaling. 
 
Discussion  
 Genetically modified mouse models have unveiled several genes involved in heart development 
and in regulation of adult heart physiology. However, key players for adult heart function and 
homeostasis remain to be uncovered. Their identification would allow the discovery of key 
mechanisms that will be helpful for a better understanding of heart dysfunction, for its use in diagnosis 
and for regenerative interventions. HGF/Met is an attractive signal as administration of exogenous 
HGF has a cardio-protective role in models of heart damage [12-14]. By exploring in vivo the role 
played by Met in heart during embryogenesis and in adulthood through selective inactivation of the 
met gene in cardiomyocytes, we demonstrated that whereas it is not essential for heart development, 
Met is required for heart homeostasis in adult mice. Intriguingly, Met becomes progressively required 
during aging. Thus, whereas 3 months old α−MHCMet mutant hearts are normal, hearts from 6 
months old males show an increase in cardiomyocyte size and myocardial fibrosis. Molecular markers 
of cardiac damage such as ANF, β-MHC, or Cx43 were up-regulated in α−MHCMet males. This was 
accompanied by abnormal ECG (S-P segment depression), a feature reported in rats with 
isoproterenol-induced cardiac hypertrophy [44]. As age increases, lack of HGF/Met signaling impacts 
heart function, and 9 months old α−MHCMet males suffer systolic left ventricle dysfunction. We 
found that Met regulates antioxidant enzymes and mitochondrial content and/or activity. Hence, heart 
anomalies are associated with down-regulation of antioxidant enzymes, leading to increased oxidative 
stress. We highlighted a significant reduction in protein levels and enzymatic activities of catalase and 
SOD-2 in the heart of α-MHCMet mutants, paralleled by ROS accumulation, first in males and later in 
females. The delayed dysfunction observed in α−MHCMet females is most likely due to the existence 
of estrogen-induced cardio-protective mechanisms, which have been extensively studied [32-34] and 
which might partially compensate HGF/Met requirement for heart function in young females.  
10 
 
 The cardio-protective role of Met during aging and in the absence of experimentally induced 
damage agrees with the function proposed for HGF/Met under pathological conditions such as 
myocardial infarction [12, 14], ischemia/reperfusion injury [13], or other models of cardiomyopathy 
where fibrosis is produced [16]. However, in all these studies it was not possible to clarify in which 
cell types HGF/Met signaling was required, as HGF can activate Met in most of the cell types present 
in the heart. Thus, some of the HGF effects previously described could be mediated by Met activation 
in non-cardiomyocyte cell types, such as fibroblasts, coronary endothelium or vascular smooth 
muscle. It is also important to highlight that HGF is a potent pro-angiogenic factor and its effect 
promoting neovascularization would be cardioprotective per se [45]. The inhibition of Met signaling 
in myocardium, leaving intact the angiogenic roles of HGF on the coronary endothelium, allows to 
discard that the observed phenotype can be due to a vascular defect. Thus, our genetic mouse model 
determines in vivo a cell autonomous requirement of HGF/Met signaling in cardiomyocytes for their 
maintenance and function. Although our results clearly suggest a direct effect of HGF on mature 
cardiomyocytes, we cannot formally exclude that HGF signaling be required for the expansion of 
cardiomyocyte progenitors as they express α−MHC [46]. In fact, the improved heart functionality 
induced by HGF treatment in doxorubicin-induced cardiomyopathy [15] or the regeneration produced 
in an infarcted myocardium [47,48], could be explained by enhanced myocardial progenitor cells 
proliferation and/or migration. If the effect on cardiomyocyte progenitors is confirmed, HGF/Met 
signaling not only would be cardioprotective, but it would be also critically involved in cardiac 
homeostasis.    
 The herein described property of HGF/Met signaling to protect cardiomyocytes from ROS-
induced damage agrees with previous studies performed under non-physiological conditions. For 
example, HGF protects cultured adult rat cardiomyocytes from apoptosis induced by oxidative stress 
upon serum deprivation, treatment with daunorubicin, or hydrogen peroxide [49].  A role for HGF 
preventing heart fibrosis has been previously described in the cardiomyopathic Syrian hamster [16]. In 
this pathological model, HGF down-regulation in endothelial and interstitial cells triggered TGF-β1 
up-regulation and interstitial fibrosis, whereas HGF treatment decreased TGF-β1 expression and 
suppressed fibrosis. We herein show that in adult heart under physiological conditions, HGF/Met 
signaling in cardiomyocytes is also essential to prevent fibrosis. Furthermore, we demonstrate a 
negative correlation between Met activity and levels of the pro-fibrotic factors such as TGF-β2 and 
TGF-β3. We also provide evidence that TGF-β treatment leads to down-regulation of antioxidant 
enzymes in cultured cardiomyocytes, thus linking fibrosis and oxidative stress. 
 The ability of HGF/Met to regulate antioxidant defenses has been reported also in other cell 
types [39-41]. For example, in vivo hepatocyte-specific Met deletion unbalances ROS regulation and 
sensitizes cells to Fas-mediated apoptosis [39]. HGF treatment also leads to increased mitochondrial 
activity and mass in glioblastoma cells [50]. The link between increased ROS levels and mitochondrial 
dysfunction in defective hearts is supported by other studies [51-54]. Therefore, it is tempting to 
speculate that mitochondrial functional alterations occurring in Met deficient cardiomyocytes could 
cause inappropriate antioxidant capability, leading to increased oxidative stress.  
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 The effects of Met inactivation in cardiomyocytes remarkably resemble heart defects in Sirt3-
deficient mice [43]. These mice are also affected by cardiac hypertrophy, fibrosis, and ROS 
accumulation as a consequence of the decrease in catalase and SOD-2 expression [43]. In agreement 
with Sirt3 and Met ability to prevent cardiac hypertrophy by suppressing ROS accumulation, SOD-2 
deficient mice die few days after birth due to dilated cardiomyopathy, despite normal heart 
development [53]. Future studies will clarify whether there is a signaling and/or a genetic link between 
Met and Sirt3.  
 We also present in vivo and in vitro evidences supporting a role for p38 MAPK in the 
antioxidant effect of HGF/Met in cardiomyocytes. So, HGF is unable to increase SOD-2 and catalase 
expression and to prevent their down-regulation by TGF-β in cardiomyocytes unless p38α MAPK is 
present. This is in agreement with the observed decrease in p38 MAPK activation and in the 
expression of these antioxidant enzymes in the heart and in cardiomyocytes lacking Met signaling. All 
this is consistent with the previously reported role of p38α MAPK as a mediator of SOD-2 and 
catalase expression in response to oxidative stress in MEFs [42]. 
 In summary, our studies evidence the cell autonomous requirement of HGF/Met signaling in 
cardiomyocytes to ensure heart function in adult mice by preventing oxidative stress-induced damage. 
Our findings open a new perspective to further explore HGF/Met as putative diagnostic markers of 
individuals subjective to heart defects and as therapeutic intervention to treat cases of idiopathic 
cardiomyopathies.  
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Figure legends 
Fig. 1 Conditional deletion of c-Met in cardiomyocytes allows normal development and function of 
the heart in mice. a: Left panel: Representative PCR showing a deletion specific band detected in 
conditional knockout (α-MHCMet) E15.5 embryo, but not in wt control (met flox/flox). Right panel: 
Western blot analysis of c-Met protein levels.  b and c:  Heart sections from wt and α-MHCMet 
E15.5 embryos (B) and newborn mice at P2 (C) stained with hematoxylin/eosin 
Fig. 2 Met inactivation in cardiomyocytes leads to cardiomyocyte hypertrophy, fibrosis and apoptosis 
in adult mice. c: Heart sections from wt and α-MHCMet males (3 and 6 months old) stained with 
hematoxylin/eosin. b: Representative laminin immunostaining of heart sections from 6 months (mo) 
old males (wt and α-MHCMet). c: Histogram showing the mean values ±SEM of the transverse 
cardiomyocyte area in 6 and 9 months old male hearts. Differences between wt and α-MHCMet are 
significant (**p<0.01). d: Mallory's trichrome staining of collagen. Fibrotic areas (in blue) are present 
in 6 months old α-MHCMet male hearts. e: Histogram showing the mean values ±SEM of the fibrotic 
cardiac surface in 6 and 9 months old male hearts (wt and α-MHCMet). **p<0.01, wt as compared 
with α-MHCMet. f: Immunolocalization of active caspase-3 in 6 months old male hearts. Positive 
cells (arrows) can be observed in the fibrotic areas of α-MHCMet hearts. Some of them show 
remaining desmin immunoreactivity (in green), suggesting they are apoptotic cardiomyocytes. Note 
the depletion of desmin in cardiomyocytes from the fibrotic areas. g: Quantification of ANF, β-MHC 
and Cx43 mRNAs by RT-qPCR in hearts from 3 and 6 months old males, comparing α-MHCMet with 
wt of the same age. RQ values ±SEM are shown in the histogram. A significant increase (***p<0.001) 
is produced in 6 months old MHCMet males. h: Significantly increased (*p<0.05) expression of TGF-
β2, TGF-β3 and Acta2 mRNAs in 6 months old mutant males as compared with wt by RT-qPCR 
(mean RQ values ±SEM are shown) 
Fig. 3 Conditional deletion of c-Met in cardiomyocytes leads to heart dysfunction in 9 months old 
mice. a: Representative electrocardiogram (ECG) of an α-MHCMet compared with a wt male (6 
months old). The figure shows a negative deflection in the S-P segment (a) and an increased P wave 
(b). b: Echocardiography analysis in 9 months old males. The following parameters are shown: IVS, 
interventricular septum thickness; LVPW, left-ventricular posterior wall thickness; LVDd, left-
ventricular diastolic dimension; LVDs, left-ventricular systolic dimension; LVDEV, left-ventricular 
end-diastolic volume; LVESV, left-ventricular end-systolic volume; LVM, left ventricular mass. All 
data are expressed as mean ±SEM. *p<0.05, wt as compared with α-MHCMet. C: Representative 
echocardiographic images of an α-MHCMet compared with a wt male 
Fig. 4 Changes in anti-oxidant enzymes, ROS levels and mitochondrial proteins in adult α-MHCMet 
male hearts. a: Representative Western-blot analysis of catalase and superoxide dismutase-2 protein 
levels in α-MHCMet and wt hearts from 6 and 9 months old males normalized with β-actin. 
Densitometry of these blots is shown (catalase and SOD-2 versus β-actin) (n=4); *p<0.05, wt as 
compared with mutants. b: Catalase and SOD-2 activities from 6 months old males is shown as the 
percentage of the activities of wt hearts (mean values ±SEM), ***p<0.001, wt as compared with 
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mutants (n=4). c: Representative sections showing accumulation of ROS (detected by 2-hydroethidine 
staining) in cardiomyocytes from 6 months old mutant males. d: Histograms show the mean 
values±SEM of the number of  2-hydroethidine stained nuclei by microscopy field in cardiac tissue 
sections from 6 months old males (left) and the percentage of 4-OH-nonenal immunoreactive surface 
in hearts from 9 months old males (right). *p<0.05 and **p<0.01, wt as compared with mutants. e: 
Histograms represent the fold increase of carbonylated protein levels (mean values ±SEM) referred to 
wt males (6 months old) ***p<0.001, mutant as compared to wt mice. f: Representative cytochrome c 
and porin western-blots (left) and densitometry of blots (porin and cytochrome c versus β-actin) (right) 
from 6 months old male hearts (n=4). *p<0.05 and **p<0.01, wt as compared with mutants. g: 
Cytochrome c oxidase activity is significantly decreased (***p<0.001) in 6 months old mutant as 
compared with wt males. Histograms represent the percentage of the activities in the mutants as 
compared to wt (mean values ±SEM) 
Fig. 5 HGF/Met signaling increases antioxidant enzymes in cardiomyocytes acting through 
p38αMAPK. Effect on TGF-β mediated down-regulation. a: Representative Western-blot analysis of 
P-p38MAPK and total p38 in hearts from 6 and 9 months old males (left) and densitometric analysis 
of blots (referred to β-actin, n=4). b and c: Representative Western-blot analysis of catalase, 
superoxide dismutase-2, P-p38MAPK and total p38 protein levels in wt and p38α-/- cardiomyocytes 
treated with the c-Met inhibitor, SU11274 (3 days) and/or HGF (16h pre-incubation), as indicated. 
Densitometric quantification of these blots is shown (referred to β-actin). d and e: Representative 
Western-blot analysis of catalase, superoxide dismutase-2 and P-p38MAPK protein levels in wt and 
p38α-/- cardiomyocytes maintained in the absence or presence of TGF-β (3 days) and/or HGF (16h 
pre-incubation), as indicated. Densitometric quantification of these blots is shown (referred to β-actin) 
Fig. 6 Treatment with antioxidants partially prevents the increase in cardiomyocyte cell size induced 
by Met inhibition. Immortalized neonatal wt cardiomyocytes were maintained in the absence or 
presence of the c-Met inhibitor SU11274 and/or N-acetyl cysteine for 1 or  4 days as indicated. a: 
Representative phase-contrast microscopy images after 1 day of treatment. b: Quantification of 
cardiomyocytes size after treatment, expressed as arbitrary units (***p<0.001) 
 
Figure 1 
A 
met flox/flox 
wt (flox/flox)  
deletion 650 
380 
w
t 
a
-M
H
C
M
e
t 
c-Met 170KDa 
140KDa 
b-actin 
w
t 
a
-M
H
C
M
e
t 
wt                           a-MHCMet 
E
1
5
.5
 
B 
P
2
 
C 
H
E
 
wt a-MHCMet 
A 
B C 
6 months 9 months 
F
ib
ro
ti
c
 s
u
rf
a
c
e
 (
%
) 
** 
M
a
ll
o
ry
's
 t
ri
c
h
ro
m
e
  
s
ta
in
in
g
 
D E 
F 
0 
100 
200 
300 
400 
500 
S
u
rf
a
c
e
 (
m
ic
ro
n
s
2
) ** ** 
R
Q
 (
a
-M
H
C
M
e
t/
w
t)
 
0 
0,5 
1 
1,5 
2 
2,5 
3 
6 months 9 months 
b-MHC 
Cx43 
ANF 
3 months 6months 
0 
5 
10 
15 
** 
L
a
m
in
in
  
C
a
s
p
a
s
e
 3
 
G 
0 
2 
4 
6 
8 
H 
6 months 
TGF-b3 
Acta2 
TGF-b2 
Figure 2 
R
Q
 (
a
-M
H
C
M
e
t/
w
t)
 
wt a-MHCMet 
*** 
A 
wt a-MHCMet 
B 
0.0 0.1 0.2 0.3
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
0.8
1.0
Seconds
m
V
0.0 0.1 0.2 0.3
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
0.8
1.0
Seconds
m
V
a 
b 
Figure 3 
wt 
a-MHC Met 
C 
Echocardiographic  
Analysis 
Control male MHCmet male 
n 4 4 
Age (months) 9 9 
Body weight (g) 53.73 ± 4.67 60.0 ± 6.11 
Heart rate (bpm) 680 ± 29.23 644 ± 28.18 
IVS (mm) 0.90 ± 0.05 1.0 ± 0.00 
LVPW (mm) 1.03 ± 0.06 1.03 ± 0.07 
LVDd (mm) 3.15 ± 0.18 3.23 ± 0.12 
LVDs (mm) 1.55 ± 0.07 1.77 ± 0.03* 
LVEDV (µl) 39.89 ± 5.76 42.19 ± 3.72 
LVESV (µl) 6.67 ± 0.83 9.28 ± 0.44* 
Stroke volumen (µl) 33.22 ± 5.08 32.91 ± 3.29 
Cardiac output 
(ml/min) 
22.59 ± 3.64 21.38 ± 2.95 
Shortening fraction 
(%) 
59.28 ± 1.62 44.33 ± 1.76* 
Ejection fraction (%) 92.65 ± 0.94 81.90 ± 1.63* 
LVM (mg) 84.01 ± 9.83 94.17 ± 6.08 
LVM/BW (mg/g) 1.56 ± 0.09 1.75 ± 0.08 
9 months 
6 months 6 months 
wt 
LVDd LVDs 
LVDs LVDd 
Figure 4 
6 months  9 months 
catalase 
SOD-2 
b-actin 
w
t 
a
-M
H
C
 
M
e
t 
w
t 
a
-M
H
C
 
M
e
t 
A 
C 
0 
20 
40 
60 
80 
100 
120 
C
a
ta
la
s
e
  
a
c
ti
v
it
y
 (
%
) 
0 
20 
40 
60 
80 
100 
120 
S
O
D
 a
c
ti
v
it
y
 (
%
) *** 
*** 
wt a-MHCMet 
6 months 6 months 
6 months 
B 
D 
0 
10 
20 
30 
40 
50 
60 
70 
R
O
S
 (
p
o
s
it
iv
e
 c
e
ll
s
) 
6 months 
wt 
a-MHCMet 
wt a-MHCMet 
* 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
9 months R
O
S
 (
%
 p
o
s
it
iv
e
 s
u
rf
a
c
e
) 
0 
1 
2 
3 
4 
5 
C
a
rb
o
n
y
la
te
d
 p
ro
te
in
s
 
(f
o
ld
 i
n
c
re
a
s
e
) 
** 
*** 
E 
Cyt c 
b-actin 
Porin 
w
t 
a
-M
H
C
 
M
e
t 
6 months 
6 months  
F 
0 
20 
40 
60 
80 
100 
120 
6 months C
it
 c
 o
x
id
a
s
e
 a
c
ti
v
it
y
 (
%
) 
G wt 
a-MHCMet 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
1,4 
* 
** 
cytc   porin 
wt 
a-MHCMet 
D
e
n
s
it
o
m
e
tr
y
/b
-a
c
ti
n
 *** 
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
1,4 
* 
D
e
n
s
it
o
m
e
tr
y
/b
-a
c
ti
n
 
wt a-MHCMet 
cat SOD cat SOD 
6 months  9 months 
* 
* * 
Figure 5 
b-actin 
w
t 
a
-M
H
C
 
M
e
t 
w
t 
a
-M
H
C
 
M
e
t 
P-p38MAPK 
6 months  9 months 
wt     p38a-/- 
catalase 
SOD-2 
b-actin 
P-p38MAPK 
SU11274   -    +     -     + 
Catalase/b-actin     0.6    0.4   0.35  0.35 
SOD-2/b-actin         0.5    0.3   0.1    0.1       
P-p38/b-actin          0.4    0.2     0      0 
A 
wt                  p38a-/- 
HGF           -      +     -      +     -     +     -    + 
SU11274    -      -      +      +     -     -     +    + 
catalase 
SOD-2 
b-actin 
wt     p38a-/- 
TGFβ    -    +     -     + 
catalase 
SOD-2 
b-actin 
P-p38MAPK 
catalase/b-actin     0.6   0.4   0.3   0.1 
SOD-2/b-actin        0.4   0.2   0.2   0.1 
 P-p38/b-actin        0.7   0.6     0     0         
B 
catalase 
SOD-2 
b-actin 
wt                  p38a-/- 
HGF         -     +     -     +     -     +     -    + 
TGF-b      -      -     +    +     -      -     +    + 
D 
C 
E 
Catalase/b-actin     0.5    0.9    0.3    0.3     0.3   0.2    0.3   0.4 
SOD-2/b-actin         0.4    0.7    0.3    0.6     0.2   0.2    0.2   0.2 
Catalase/b-actin     0.5    0.9    0.3    0.7    0.3   0.3    0.3   0.4 
SOD-2/b-actin         0.4    0.7    0.3    0.6    0.2   0.2    0.2   0.2 
0 
0,5 
1 
P
-p
3
8
M
A
P
K
/b
-a
c
ti
n
 
wt 
a-MHCMet 
6 months  9 months 
* ** 
p38 MAPK 
p38 MAPK 
p38 MAPK 
Figure 6 
Control NAC SU11274 NAC+SU11274 
1 day 
0 
5000 
10000 
15000 
20000 
25000 
30000 
35000 
Control NAC SU NAC+SU 
c
e
ll
 s
iz
e
 (
a
rb
it
ra
ry
 u
n
it
s
) 
1 day 
4 days 
*** *** 
A 
B 
DETAILED METHODS 
Generation of cardiomyocyte c-met knock-out mice and genotyping 
 c-met flox/flox mice (generated on a CD1 genetic background), which carries c-met 
alleles with exon 16 flanked by loxP sites was obtained from Dr. S. Thorgeirsson (Huh et al. 
2004). This mouse line were crossed with α-MHC-Cre mice (obtained from Dr. M. D. 
Schneider) to generate a conditional Knock-out of c-met in cardiomyocytes. Cre-mediated 
excision led to a null allele for c-met, which encodes an inactive c-Met receptor only in 
cardiomyocytes (α-MHCMet mice). We used these mice for our analysis, as well as wt mice 
(Met flox/flox and α-MHC-Cre), using in total 120 mice. 
 Mice genotyping was performed by PCR analysis using genomic DNA from tails, 
embryonic membranes or hearts. The following oligonucleotides were used to amplify the 
floxed allele (380 bp) and wt allele (300 bp): Met-lox1: 5' TTAGGCAATGAGGTGTCCCAC 3' 
and Met-lox2: 5' CCAGGTGGCTTC AAATTCTAAGG 3'; and for the deleted allele (650 bp): 
Met-lox1 and Met-lox3: 5' CAGCCGTCAGAC AATTGGCAC 3'. In addition, Cre was 
amplified using the following primers: forward 5' AGG TGT AGA GAA GGC ACT TAG C 3' 
and reverse 5' CTA ATC GCC ATC TTC CAG CAG G 3'. 
 DNA from tails and embryonic membranes was isolated by digestion in extraction 
buffer (50mM KCl, 1.5mM MgCl2, 10mM Tris HCl pH 8.5, 0.01% gelatine, 0.45% NP40 and   
0.45% Tween 20) containing proteinase K (100µg/ml) at 56°C o/n for tails or 30-45 min for 
embryonic membranes, while DNA from hearts was obtained using AllPrep DNA/RNA/Protein 
Mini Kit (Quiagen, 80004). 
 
RT-qPCR analysis  
 After the isolation of total RNA, DNA and proteins using AllPrep DNA/RNA/Protein 
Mini Kit (Quiagen, 80004), 1-3 µg of RNA was reverse transcribed using SuperScript III RT kit 
(Quiagen, 18080) to generate cDNA. Then, quantitative PCR analysis was performed by Real 
Time PCR using SYBR Green (Roche) and the following specific primers. For ANF: forward: 
5´TCCTAGCCAGTCTCCAGAGC3´ and reverse: 5´TTTGGGTGTTCTTTTGTGAGG3´; β-
MHC: forward: 5´GGACCTTGGAAGACCAGATG3´ and reverse: 
5´CGGGTTAGCTGAGAGATCAGAG3´; Connexin 43: forward: 5´AGT 
CCTTCCCCATCTCTCAC3´ and reverse: 5´GCTTCTCTTCCTTTCTCATCAC3´; TGF-β2: 
forward: 5´GCCGAGCAGCGGATTGAACTGTA3´ and reverse: 
5´AGCCATTCACCCTCCGCTCT3´, TGF-β3: forward: 
5´CGGGAGTTGCTGGAAGAGATGC 3´ and reverse: 5´TCATTGTGCTCCGCCAGTCCCT 
3´;  Acta 2 (α-Smooth muscle actin) forward: 5´AGAGTGGAGAAGCCCAGCCAGT 3´and 
reverse: 5´AGAGCCCAGAGCCATTGTCGCA3´.  The amplified bands were normalized using 
as an internal control, GAPDH, forward: 5’-CATCAAGAAGGTGGTGAAGC-3’ and reverse: 
5’-CATCGAAGGTGGAAGAGTTGG-3’ in the same PCR reaction. Quantification was 
performed through calculation of RQ (2-ΔΔCt). Ct (threshold cycle) for a primer minus -Ct for 
GAPDH =ΔCt and then, this is referred to wt control values (KO ΔCt-wt ΔCt= ΔΔCt) to 
calculate RQ value.  
 In addition, an Invitrogen custom RNA profiling by RT-qPCR was performed in order to 
analyze more genes: pro-fibrotic genes, Acta2 (α-SMA) and Snail; anti-fibrotic genes (Bmp7, 
Hgf); genes from TGF-β superfamily (Smad2, Smad3, Smad4, Smad6, Smad7,Tgfβ1, Tgfβ2, 
Tgfβ3, Tgfβr1/ALK5, Tgfβr2) and different genes involved in the regulation of ROS 
metabolism (Nox1, Nox4, Noxa1, Noxo1, Gpx1, Gpx2, Gpx3, Cat, Sod1, Sod2, Sod3).  
However, we just found significant differences in the expression of Tgfβ2, Tgfβ3 and Acta2 
mRNAs, but not in the rest of the genes.  
 
Western-blot analysis 
  Western-blot analysis was carried out as previously described (Zuluaga et al., 2007) 
using total cell extracts. Proteins were separated by electrophoresis using Anderson gels (or 
SDS-page gels) and transferred to nitrocellulose membranes that were probed with the 
following antibodies: catalase (Sigma, C-0979), SOD-2 (Upstate Biotech, 06-984), β-actin 
(Sigma A5441), c-Met (Sta. Cruz Biotechnology sc-260), cytochrome c (BD 556433); porin 
(Sigma V2139). 
 
Histology 
 Embryos and adult hearts were processed for histology using conventional techniques of 
paraformaldehyde fixation and paraffin embedding. Haematoxylin-eosin and Mallory’s 
trichrome staining were performed on deparaffinated sections. Laminin immunohistochemistry 
was used to delineate the cardiomyocyte profiles. Briefly, deparaffinated 10 µm sections were 
rehydrated, blocked with 16% sheep serum in Tris-PBS, and incubated o/n at 4ºC with a rabbit 
polyclonal anti-laminin antibody (Sigma L9393). After washing, sections were incubated with a 
fluorochrome conjugated anti-rabbit IgG antibody, washed, and observed in a Leica confocal 
microscope. Image analysis was performed on confocal images from the laminin 
immunostaining, in areas where the cardiomyocytes were transversely sectioned. 
Cardiomyocyte profiles were hand-drawn on a transparent mask placed on the images using 
Photoshop software. The inversion of these images provided spots corresponding to the 
cardiomyocyte sections. The area of these spots was measured using the image analysis package 
Image J.  
 Detection of activated caspase-3, a marker of apoptosis, was performed through 
immunohistochemistry using a rabbit polyclonal antibody from Promega (G74819. For double 
staining, of apoptotic cardiomyocytes and anti-desmin antibody (Sigma) was used. The degree 
of interstitial fibrosis was assessed by image analysis on trichrome stained tissue sections. 
Collagen is stained in blue and myocardiocytes in red. Digital images were obtained from three 
specimens by group (mutant/wildtype, males/females). RGB channels were split, and the red 
channel (where blue color appears as dark grey) was analyzed using the ImageJ package. A 
uniform threshold level was applied to all the figures, and the originally blue (i.e. fibrotic) areas 
appeared as black surfaces. The percentage of the black surface relative to the total surface was 
determined and mean value and standard deviation was obtained for each group. 
 
ROS detection and quantification  
 ROS accumulation in the heart was detected upon staining of frozen sections with 1µM 2-
hydroethidine (in PBS) for 20 min at 37ºC in the dark. The sections were then washed with 
PBS, mounted and analyzed by fluorescence microscopy. The number of stained nuclei was 
counted on digitalized images using ImageJ software. In addition, carbonylated proteins were 
quantified as an indirect measurement of ROS (Richert et al., 2002). Basically, heart extracts 
were treated with 10 mM 2,4- Dinitrophenylhydrazine (DNPH) in 2M HCl (Sigma D-2630) for 
1h at room temperature in the dark. As a control, half of the sample was not treated with DNPH 
(blank). Then, proteins were precipitated with 10% TCA. Pellets were washed 3 times with 
ethanol: ethyl-acetate, resuspended in 6M guanidine at pH 2.5 and the absorbance at 360 nm 
was determined. The concentration of carbonylated proteins for each sample was calculated 
upon correction with the blanks (extinction coefficient=22000 nmol/l/cm) and was referred to 
protein content.  
 In 9 months old mice, oxidative stress was assessed on paraffin sections by 
immunohistochemistry using an anti 4-hydroxynonenal antibody (HNE11-S, Alpha Diagnostic 
International). Stained areas of the tissue were also assessed by image analysis. 
 
Measurement of catalase and SOD activities  
 Catalase activity was measured by quantification of peroxide decomposition in a 50 mM 
phosphate buffer at pH 7 containing 3mM H2O2. This was monitored spectrophotometrically at 
240 nm. SOD activity from cell extracts was quantified using a Kit (BioVision, ref. #K335-
100), where WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H tetrazolium, 
monosodium salt) is the substrate. WST-1 produces a water-soluble formazan dye upon its 
reduction with superoxide anion, which can be monitored spectrophotometrically at 450nm. 
This rate of reduction is linearly related to the xanthine oxidase activity and inhibited by SOD, 
so the IC50 of SOD is determined as a measure of SOD activity. 
 
Electrocardiographic measurements in conscious mice using radiotelemetry 
 Electrocardiograms (ECGs) were performed in conscious mice using a radiotelemetry 
system (Data Science International, St Paul, MN, USA). Mice were anaesthetized and a 
radiotelemetry transmitter (PhysioTel® model EA-F20, Data Science International) was 
implanted in the scruff of the neck, with the negative lead sutured in the muscle just under the 
right clavicle and the positive lead placed left of the xiphoid process. The mice were housed in 
individual cages for at least 5 days post-implantation before ECG recordings were obtained. 
Recordings were taken every 3 h, for a duration of 5 min/each, over a 24 h period, during which 
the mice had access to food and water ad libitum and were exposed to a 12 h light–dark cycle. 
Analysis of the recording was performed using ECG-auto software supplied by Data Systems. 
 
Ecocardiographic assessment of cardiac function and structure 
 Transthoracic echocardiography was performed using an Vivid 7 (GE Medical Systems) 
cardiac ultrasound machine equipped with a 10-14-MHz transducer il3L (GE Medical Systems) 
by a single experienced operator who was blinded to the mice genotype, as previously described 
(Grande et al. 2011). In brief, mice were lightly sedated by intraperitoneal administration of a 
combination of ketamine, atropine and midazolam and maintained on a heated platform. Heart 
rates are generally maintained at more than 500 per minute with these regimens. Each mouse 
was gently held in the palm of the hand by securing the skin of the dorsal neck with the thumb 
and the index finger, and securing the tail between the handler’s last two fingers. While in the 
supine position the hair chest was removed and prewarmed hypoallergenic gel was applied in 
order to improve the ultrasonic penetration and the quality of images. Animal handling care was 
taken to minimize excessive pressure of the transducer on the chest wall and to avoid reflex 
bradycardia.  
 Two dimensional images were recorded in long and short axis projection with guided M-
mode recordings at the level of the papillary muscle.  Generally the sweep speed was of 200 
mm/s and image depth of 10 mm. Left ventricular (LV) cavity size and wall thickness were 
measured using the leading-edge technique adopted by the American Society of 
Echocardiography, in at least three beats (3-5) from each projection and averaged.  
 LV wall thickness {interventricular septum (IVS) and posterior wall (PW) thickness} and 
internal dimensions at diastole and systole (LVEDD and LVESD), respectively, were measured. 
LV fractional shortening was calculated as {(LVEDD-LVESD)/LVEDD}x100, LV ejection 
fraction as (LVEDV-LVESV/LVEDV*100), LV mass as {1.05x{(PW+AW+LVEDD)3-
(LVEDD)3}, and relative wall thickness (RWT) as {(2xPW)/LVEDD}. End-diastolic and end-
systolic volumes, LVEDV and LVESV respectively {7/(2.4+LVEDV) x LVEDV3}, stroke 
volume (LVEDV-LVESV) and cardiac output (heart rate x stroke volume) were also 
determined. 
 Measurements of chamber dimensions and cardiac function were made offline (EchoPac 
Software, GE Medical Systems) and all echocardiographic parameters were averaged from at 
least three cardiac cycles. 
 
Assays in cardiomyocytes derived cell lines 
 Cardiomyocytes cell lines (wt and p38α-/-) were previously generated from E9.5 
embryos mice and they express a temperature-sensitive large T antigen (LTAg) under control of 
interferon-γ (IFN-γ). Before the experiments, cells were transferred to 37°C in the absence of 
IFN-γ to abolish LTAg expression. Neonatal cardiomyocyte cell lines were obtained by 
immortalization of neonatal mice (P4) cardiomyocytes by transfection with LTAg. All the cell 
lines were maintained in a low serum medium (2-3%) and treated with the Met inhibitor 
SU11274 (5µM) or TGF-β (1ng/ml) in the presence or absence of HGF (30ng/ml, 16h 
pretreatment) or N-acetyl cysteine (2.5mM) for 1-5 days as indicated.  
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SUPPLEMENTAL FIGURES 
 
Supplemental figure 1-Six months old α-MHCCre male mice showed no differences in cardiac 
damage when compared with Met flox/flox (wt) male mice: 
 
A-Analysis of ANF, β-MHC and Cx43 mRNA expression by RT-qPCR shows no significant 
differences between α-MHCCre and Met flox/flox (wt) male mice.  
 
 
 
B-SOD-2, catalase and cytochrome c protein levels are similar in 6 months old α-MHC-Cre and 
Met flox/flox (wt) male mice:  
 
Western-blot analysis of catalase, SOD-2 and cytochrome c in total heart extracts from 6 
months old male mice (n=3). Blots were quantified by densitometric analysis of the bands 
(catalase, SOD-2 and cytochrome c) and normalized with β-actin. Then, the normalized values 
for α-MHC-Cre were expressed as the percentage of Met flox/flox values, which were 
considered as 100% (histogram). No significant differences in the expression of these proteins 
were detected between α-MHC-Cre and Met flox/flox male mice. 
 
 
ANF, β-MHC and Cx43 RQs (comparing α-
MHC-Cre  with Met flox/flox ) are shown. 
There are no significant differences in the 
expression of these mRNAs between α-
MHC-Cre and Met flox/flox male mice at 
the age of six months (n=3). 
 
 
Supplemental figure 2-Images showing cardiomyocytes hypertrophy and fibrosis in 9 months 
old α-MHCCre mutant males: 
 
A-Representative laminin immunostaining (green and nuclei in blue) of hearts from 9 months 
(mo) old males (wt and α-MHCMet). 
 
B-Mallory's trichrome staining of collagen. Fibrotic areas are visualized in blue in α-MHCMet 
(9 months (mo) old males). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 3-Met inactivation in cardiomyocytes leads to cardiomyocyte hypertrophy 
and fibrosis in 9 months old females. A: Representative laminin immunostaining (green, nuclei 
in blue) of hearts from 9 months (mo) old females (wt and α-MHCMet). B: Histogram showing 
the mean values ±SEM of the transverse cardiomyocyte area in 6 and 9 months old female 
hearts. Significant differences (**p<0.01) were observed in 9 months old females (wt as 
compared with α-MHCMet).  
 
 
C: Mallory's trichrome staining of collagen of heart sections from 9 months old females. 
Fibrotic areas (in blue) are present in α-MHCMet female hearts. D: Histogram showing the 
mean values ±SEM of the fibrotic area in 6 and 9 months old female hearts (wt and α-
MHCMet). Significant differences (*p<0.05) were observed in 9 months old females (wt as 
compared with α-MHCMet). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 4-Changes in anti-oxidant enzymes, ROS levels, mitochondrial proteins 
and p38MAPK activation in adult α-MHCMet female hearts.  
 
A: Representative Western-blot analysis of catalase and SOD-2 protein levels in α-MHCMet 
and wt hearts from 6 and 9 months old females normalized with β-actin. Densitometry of these 
blots is shown (catalase and SOD-2 versus β-actin) (n=4). B: Catalase and SOD-2 activities 
from 6 months old females is shown as the percentage of the activities of wt hearts (mean values 
±SEM) (n=4). 
 
C: (Left) Representative sections showing no accumulation of ROS (detected by 2-
hydroethidine staining) in cardiomyocytes from 6 months old wt and mutant females. 
Histograms show the mean values±SEM of the number of  2-hydroethidine stained nuclei by 
microscopy field  in cardiac tissue sections from 6 months old females (middle) and the 
percentage of 4-OH-nonenal immunoreactive surface in hearts from 9 months old males (right). 
Significant differences (*p<0.05) were observed in 9 months old females (wt as compared with 
α-MHCMet). 
 
D: Histograms represent the fold increase of carbonylated protein levels (mean values ±SEM) 
referred to wt (6 months old females). E: Representative cytochrome c and porin western-blots 
and densitometry of blots (porin and cytochrome c versus β-actin) from 6 months old female 
hearts (n=4). F: Cytochrome c oxidase activity in 6 months old females. Histograms represent 
the percentage of the activities in the mutants as compared to wt (mean values ±SEM). 
 
G: RepresentativeWestern-blot analysis of P-p38 MAPK and total p38 levels in α-MHCMet 
and wt hearts from 6 and 9 months old females normalized with β-actin. Densitometry of the 
blots is shown (P-p38 versus β-actin). 
 
 
